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Abstract
Cyclodextrin-based nanosponges, which are proposed as a new nanosized delivery system, are innovative cross-linked cyclodextrin
polymers nanostructured within a three-dimensional network. This type of cyclodextrin polymer can form porous insoluble
nanoparticles with a crystalline or amorphous structure and spherical shape or swelling properties. The polarity and dimension of
the polymer mesh can be easily tuned by varying the type of cross-linker and degree of cross-linking. Nanosponge functionalisa-
tion for site-specific targeting can be achieved by conjugating various ligands on their surface. They are a safe and biodegradable
material with negligible toxicity on cell cultures and are well-tolerated after injection in mice. Cyclodextrin-based nanosponges can
form complexes with different types of lipophilic or hydrophilic molecules. The release of the entrapped molecules can be varied by
modifying the structure to achieve prolonged release kinetics or a faster release. The nanosponges could be used to improve the
aqueous solubility of poorly water-soluble molecules, protect degradable substances, obtain sustained delivery systems or design
innovative drug carriers for nanomedicine.
Review
Recent advances in nanotechnology demonstrate the increased
attention that is now being paid to the supramolecular assembly
of simple components for therapeutic and diagnostic purposes.
The design of new biomaterials based on nanoscale structural
characteristics can be expected to provide many potential appli-
cations in the field of nanomedicine.
Cyclodextrins [1-3] are nanometric biomaterials with a close
relationship between molecular status and supramolecular prop-
erties. They are a class of cyclic glucopyranose oligomers and
are synthesised by enzymatic action on hydrolysed starch. The
main common native cyclodextrins are α, β and γ, which
comprise six, seven and eight glucopyranose units, respectively.
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Scheme 1: Synthetic routes to cyclodextrin nanosponges. (a) Cyclodextrin carbonate nanosponges. (b) Cyclodextrin carboxylate nanosponges.
They have a characteristic toroidal shape, which forms a well-
defined truncated cone-shaped lipophilic cavity. Cyclodextrins
are able to include compounds whose geometry and polarity are
compatible with that of their cavity.
However, native cyclodextrins are not able to form inclusion
complexes with certain molecules, such as hydrophilic or high-
molecular-weight drugs. Moreover, β-cyclodextrin, the cheapest
type, has low water solubility (1.85% w/v at 25 °C) and is toxic
when injected intravenously. Consequently, many chemical
modifications of cyclodextrins have been studied in an attempt
to overcome their limitations and improve their technological
characteristics. Well-structured molecules as well as random
mixtures are described in the literature [4], and dimers [5],
trimers [6], and polymers have also been obtained [7].
A different approach is to synthesise cross-linked cyclodextrin-
based polymers so as to prepare insoluble multifunctional
cyclodextrin derivatives [8-10]. These polymers can be obtained
by reacting native cyclodextrins with a cross-linking agent that,
after reaction, exerts its own properties and influences the
behaviour of the cyclodextrin unit. Although insoluble cross-
linked cyclodextrin polymers were first reported a long time
ago, by reacting the parent cyclodextrin with dialdehydes, epox-
ides, epichlorohydrin, diacyl chlorides, etc., the term cyclodex-
trin nanosponges were first used by DeQuan Li and Min Ma in
1998 [11] to indicate a cross-linked β-cyclodextrin with organic
diisocyanates leading to an insoluble network that showed a
very high inclusion constant with several organic pollutants. For
instance, p-chlorophenol was almost completely removed from
waste water even at the parts per billion level [12]. However, no
other applications were claimed or proposed.
It was not until the work performed by Trotta and co-workers
[13] and the syntheses of new kinds of cyclodextrin
nanosponges that they revealed their full potential in other
fields, particularly as drug carriers.
Generally speaking, nanosponges are hyper-cross-linked
cyclodextrins that can be obtained with α, β and γ cyclodextrins,
either alone or as mixtures containing relevant amounts of
linear dextrin, cross-linked with a suitable cross-linking agent.
Interesting results have already been obtained as drug carriers
by using an active carbonyl compound, e.g., carbonyldimiida-
zole, triphosgene, diphenyl carbonate, or organic dianhydrides
(Scheme 1).
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Detailed reaction conditions and parameters are reported else-
where [14]. Here we simply wish to stress that primary hydroxy
groups are mainly involved in the formation of a network as
shown by FTIR–ATR, Raman and solid-state NMR analyses
[15]. Moreover, the elastic properties of cyclodextrin
nanosponges were determined by analysis of the spectral modi-
fication of the Boson peak and Brillouin frequency [16]. Using
ultrasound-assisted synthesis and a suitable cross-linker molar
ratio, spherical nanosponges of submicron size were obtained
[17]. The cross-linking produces a powder consisting of
cyclodextrin connected by nanochannels to form a cage-like
structure (Figure 1).
Figure 1: Molecular structure of cyclodextrin carbonate nanosponges.
By using different amounts of cross-linking agent, or by
changing the type of cyclodextrin, it is possible to modulate the
channels between the cyclodextrin molecules, thereby tuning
the formation of the porous network and consequently affecting
both the inclusion capacity and the solubilising ability of the
nanosponges. Acid nanosponges carrying free carboxylic
groups can be obtained using pyromellitic anhydride or other
dianhydrides as a cross-linker, forming true cation exchange
sites. The presence of free hydroxy groups in the nanosponges
network allows further surface modification. For instance,
carboxylated nanosponges can be obtained by reacting pristine
carbonate nanosponges with succinic anhydride.
Detailed physicochemical characterisation is reported in the
literature, demonstrating that carbonate nanosponges are ther-
mally stable up to 300 °C and can therefore be sterilised by
autoclaving at 121 °C and 2 bar for 15 minutes. FTIR and NMR
analyses before and after sterilisation show their stability and
the absence of degradation [13]. In addition, they do not act as
surfactants and can be easily dispersed in water.
Nanosponges also have colloidal sizes with a mean diameter of
less than 1 µm and narrow size distribution and form opales-
cent suspensions on dispersion in water. The zeta potential of
carbonate nanosponges is about −25 mV, which is sufficiently
high to produce stable water suspensions that do not undergo
aggregation over time.
For parenteral application it is possible to synthesise
nanosponges with a mean diameter in the range of 200–300 nm
with narrow size distribution (Figure 2).
Figure 2: TEM microphotograph of cyclodextrin carbonate
nanosponge (magnification 46,000×).
The stability of carbonate nanosponges was evaluated at 60 °C
under both acidic and basic conditions. Under acidic conditions
(0.1 N HCl) a limited release of cyclodextrin units was
observed after 2 h due to degradation of the nanosponge struc-
ture, whereas the basic environment did not affect the
nanosponge stability. On the other hand, carboxylated
nanosponges obtained by using pyromellitic dianhydride as a
cross-linker appear less chemically and thermally stable, but
can swell more than 30-fold in water, they have more negative
zeta potential, and can simultaneously host cations, organic
molecules and even macromolecules.
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Preliminary toxicity studies were carried out on carbonate
nanosponges in order to assess their safety with respect to pre-
clinical studies on laboratory animals.
The methods employed for cytotoxicity testing are those
described in the literature [18].
In vitro cell culture toxicity assays were carried out on different
cell lines (i.e., HELA; MCF7, COS) by using the MTT test.
Cells were incubated for between 24 and 72 h and their viability
determined. After incubation with nanosponges no cytotoxicity
was observed. The percentage of cell viability did not change
from untreated cells. Other in vitro methods for evaluating the
toxicity of new materials include the determination of its
haemolytic properties. When nanosponges were incubated with
human erythrocytes for 90 minutes, no haemolytic activity was
observed up to a concentration of 15 mg/mL, showing that the
nanosponges possess good blood compatibility.
Acute systemic toxicity was evaluated after injection in mice.
Unlike other cross-linked cyclodextrin polymers [19],
nanosponges were found to be safe between 500 and
5000 mg/kg in Swiss albino mice: they did not show any sign of
toxicity or adverse reactions. Nanosponges were then injected
intravenously into mice and monitored for 24 h. Oral adminis-
tration of nanosponges was also tested in mice [20] with no
apparent side effects.
The nanoporous structure that is formed changes many prop-
erties of the native cyclodextrin. This peculiar and versatile
structure is suitable for a broad range of potential and actual
applications and was recently reviewed [13,21-23]. As a general
characteristic, the nanosponge structure improves the ability
of cyclodextrins to form specific complexes with guest mole-
cules, compared to native cyclodextrins. The included
substances can be either strongly retained or released in a
controlled manner.
From an environmental standpoint this means that water pollu-
tants, such as heavy metals and many organic molecules, can be
removed and retained easily [24,25].
The use of nanosponges in water treatment has been found
successful for aromatic chlorohydrocarbons, and nanosponges
succeeded where their main competitor, activated carbon,
failed, for example, in the removal of heavy metals. Further-
more, nanosponges have greater mechanical strength than acti-
vated carbon and are not affected by dust formation during
application. Finally, they can be reused indefinitely after simple
washing with an environmentally friendly solvent, such as
ethanol.
Nanosponges can be used as supports for catalysis applications.
One important result that has emerged from experiments on
enzyme catalysis is the prolonged activity of the enzymes [26].
Nanosponges can preserve the activity of some enzymes far
longer than other supporting media, such as agarose. Moreover,
the possibility of including enzymes inside the structure
prolongs their activity and makes it possible to obtain an effica-
ciously supported catalyst to promote chemical reactions and
aid the destruction of chemical pollutants (detergents, POPs
abatement) as well as biosensors.
Nanosponges can also be used in agriculture and have shown
the interesting characteristic of encapsulating some important
agricultural chemicals. In this case, release is controlled and has
a slow profile [27]. Finally, nanosponges can also be used in
polymer processing to improve flame-retardant properties
[28,29] and in enantio-differentiating photoisomerization reac-
tions [30].
Application of cyclodextrin nanosponges in
drug delivery
By virtue of their biocompatibility and versatility, nanosponges
have many potential applications in the pharmaceutical field.
One recent EU commission report focused on the use of
cyclodextrin nanosponges as a promising innovative system for
drug delivery. They can be used as excipients in preparing
tablets, capsules, pellets, granules, suspensions, solid disper-
sions, or topical dosage forms or as new nanotechnological,
multifunctional carriers [31,32].
In particular, the design of new nanodelivery systems to
improve drug administration is currently being studied. Many
drugs show poor solubility, low permeability, a short half-life,
low stability, and/or high molecular weight, and as a conse-
quence their formulation is challenging.
Nanosponges have the capacity to incorporate drugs within their
structure, either as inclusion complexes or as noninclusion
complexes. There are far more interaction sites available for
incorporation within a nanosponge structure than in β-cyclodex-
trin molecules, and they also show different mesh polarities
(hydrophobic cyclodextrin cavities surrounded by hydrophilic
nanochannels of the polymeric network) thereby enabling
significant interactions between molecules with different
lipophilicities and structures.
The ability of cyclodextrin nanosponges to encapsulate drugs
has been studied in depth for both hydrophilic and lipophilic
molecules, including dexamethasone, flurbiprofen, doxorubicin,
itraconazole, resveratrol, paclitaxel, 5-fluorouracil and tamox-
ifen, as is shown in Table 1.
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Table 1: Molecules complexed by using nanosponges.
Drug log P Therapeutic
activity
Administration route Reference
Dexamethasone 1.9 anti-inflammatory oral, parenteral [51]
Flurbiprofen 4.2 anti-inflammatory oral [51]
Doxorubicin 1.3 antineoplastic parenteral [51]
Progesterone 3.9 hormonal oral [51]
Itraconazole 5.7 antifungal oral, topical [33]
5-fluorouracile −0.9 antineoplastic parenteral, topical [40]
Tamoxifen 4.0 antiestrogen oral [34]
Resveratrol 2.8 antioxidant oral, topical [48]
Paclitaxel 2.5 antineoplastic parenteral [36-46]
Camptothecin 1 antineoplastic parenteral [41,42]
Omeprazole 2.2 antiulcerative oral [38]
Nelfinavir mesylate 4.6 antiviral oral [38]
Acetylsalicylic acid 1.2 analgesic oral [36]
Acyclovir −1.6 antiviral oral, topical, parenteral [39]
Gamma-oryizanol – antioxidant topical [49]
Telmisartan 7.7 antihypertensive oral [47]
Considering their versatility, nanosponges can act as multifunc-
tional carriers, i.e., to enhance solubility, protect fragile mole-
cules, and achieve sustained release. In many cases they act
with two or more functions simultaneously.
In this review we summarise their potential capacities by classi-
fying nanosponges according to their main applications, and
some examples are reported as case studies.
Solubility enhancement
One of the greatest limits to the development of various
pharmaceuticals is the low water solubility of many drugs.
About 40% of new drugs are poorly soluble in water, which
hinders their clinical application. The formulation of poorly
water-soluble drugs constitutes a problem that is difficult to
solve. Many technological approaches have been investigated.
The ability of cyclodextrins to form inclusion complexes with
various molecules is widely used in the pharmaceutical field as
a strategy to increase the aqueous solubility and, consequently,
bioavailability of lipophilic drugs. For hydrophilic or
moderately polar drugs this approach is less effective,
and consequently cyclodextrin derivatives have been investi-
gated.
Nanosponges can improve the wetting and solubility of mole-
cules with very poor solubility in water. The drugs can be
molecularly dispersed within the nanosponge structure and
then released as molecules, avoiding the dissolution step.
Consequently, the apparent solubility of the drug can be
increased.
Many formulation and bioavailability problems can be solved
by enhancing the solubility and dissolution rate of a substance,
and nanosponges can greatly enhance the drug solubility.
Swaminathan et al. studied a formulation of itraconazole in
nanosponges [33], a drug with an aqueous solubility of about
1 ng/mL at physiological pH. The presence of nanosponges im-
proved the solubility of the drug more than 27-fold; and when
PVP was added as an auxiliary component of the nanosponge
formulation, this rose to 55-fold. Moreover, the dissolution
profiles of the drug for the two formulations were faster than for
the formulations available on the market. Nanosponge formula-
tion could thus increase the bioavailability of itraconazole.
The solubilisation efficiency of nanosponges with regard to
tamoxifen, a nonsteroidal anti-estrogen molecule used for
treating and preventing breast cancer, was observed by using a
0.5% aqueous suspension of β-CD nanosponges [34]. Encapsu-
lation of tamoxifen in these nanosponges was more than 40%
w/w, since 5 mg of nanosponges can solubilise 2.2 mg of
tamoxifen. The in vitro release of tamoxifen from nanosponges
showed pseudo-zero order kinetics. After 2 h about 60% of the
encapsulated drug had been released at pH 7.4.
The anticancer agent paclitaxel is another drug difficult to
formulate. Paclitaxel has a very low solubility in water, i.e., less
than 0.3 μg/mL. As a consequence, the dosage form available
for clinical administration requires the use of other pharmaceu-
tical solvents or emulsifying agents, namely Cremophor EL
(polyethoxylated castor oil). Unfortunately, Cremophor EL has
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been seen to cause serious side effects, such as neurotoxicity,
nephrotoxicity and cardiotoxicity [35].
Cyclodextrin-based nanosponges were used to prepare a
Cremophor-free formulation for paclitaxel administration.
Paclitaxel-loaded nanosponges were prepared by using the
freeze-drying method to entrap the drug in a β-CD nanosponges
network. The paclitaxel solubilisation efficiency of this formu-
lation was compared to that of native β-cyclodextrin showing a
marked increase. β-CD nanosponges loaded with paclitaxel
have a mean diameter of about 350 nm with a rather narrow size
distribution (polydispersity index below 0.2).
These nanosponges obtained using carbonyldiimidazole as a
cross-linker showed good paclitaxel complexation ability: one
millilitre of a 1.5% nanosponge aqueous suspension allows one
to dissolve about 2 mg of paclitaxel, thus confirming their
wetting and solubilising properties towards paclitaxel avoiding
the use of surfactants. The paclitaxel-loaded nanosponges
formed a stable colloidal system in water inhibiting the recrys-
tallization of paclitaxel over time. Moreover, this study demon-
strated that delivery of paclitaxel via nanosponges increased the
amount of paclitaxel entering cancer cells and lowered the IC50
of paclitaxel, thereby enhancing its pharmacological effect [36].
Sustained delivery system
Modified-release dosage forms offer a number of advantages
over the conventional release formulation of a drug. The design
of a modified-release product is generally intended to optimise
the treatment regimen by providing slow, continuous delivery
of the drug over the entire dosing interval. This makes it
possible to decrease the dose administered, change the pharma-
cokinetic profile, and decrease side effects.
Different drug delivery systems have been designed to modify
the release kinetics of medicinal products. The drug release
kinetics from nanosponges can be obtained with a prolonged
release profile over time. Previous in vitro studies showed that
flurbiprofen was released slowly from β-CD nanosponges [37],
reaching a percentage of less than 10% after 130 minutes. A
similar result was obtained with the incorporation of doxoru-
bicin in nanosponges. In in vitro tests, doxorubicin was released
very slowly at pH 1.2 (about 1% after 120 minutes) and the
percentage increased with pH values. Doxorubicin release of
about 29% was obtained at pH 7.4. This behaviour could
suggest that the nanosponge formulation is able to protect the
drug from the gastric environment, allowing delivery in the
intestinal tract.
Vavia prepared nelfinavir mesylate loaded nanosponges to
enhance the solubility of the drug [38]. Nelfinavir is a protease
inhibitor with low bioavailability, used to treat HIV infections.
In this case, the drug was released more slowly from
nanosponges than from a β-CD complex. This behaviour shows
that nanosponges are able to prolong drug release over time and
consequently could also be proposed as a sustained drug-
delivery system for oral administration.
Acyclovir is a medium polarity drug with a solubility in water
of 1.5 mg/mL. Special carboxylated nanosponges, containing
dissociable carboxylic groups in their structure were developed
for its encapsulation. They represent a further electrostatic
contribution for drug encapsulation, in addition to the cyclodex-
trin cavities. Electrostatic interactions may occur between the
carboxylic groups present in the nanosponge structure and the
amino group of acyclovir.
In vitro, acyclovir-loaded carboxylated nanosponges [39]
showed prolonged release of the drug without the initial burst
effect, and 20% drug release was obtained after three hours.
Protection from light or degradation
Nanosponges can also be used as carriers to protect encapsu-
lated molecules from light or from chemical- and enzyme-
induced degradation. To evaluate the potential protection appli-
cation, 5-fluorouracile was used as a light-sensitive model drug.
β-CD nanosponges were able to incorporate up to 30% of
5-fluorouracile [40]. The in vitro release of 5-fluorouracile,
determined by using the dialysis-bag technique at pH 7.4, was
about 60% of the encapsulated amount after 2 h showing an
interaction between the drug and the nanosponge structure,
despite the hydrophilicity of the drug. Moreover, encapsulation
of 5-fluorouracile in nanosponges protected the drug and main-
tained its cytotoxicity against MCF-7 cells. Another paradig-
matic example was established with the incorporation of camp-
tothecin in cyclodextrin nanosponges.
The anti-tumour activity of camptothecin has been extensively
investigated in both hematological and solid malignancies;
however, its use is still limited due to its poor solubility and
high chemical instability since the lactone ring of the molecule
is very susceptible to hydrolysis under physiological conditions.
The encapsulation of camptothecin in nanosponges was used to
prolong the shelf life and release of the drug [41]. The
nanosponges solubilised large amounts of the drug and
protected the lactone ring from opening due to its high inclu-
sion abilities, thereby increasing stability.
Three types of nanosponges, i.e., β-CD-1/2 nanosponges, β-CD-
1/4 nanosponges and β-CD-1/8 nanosponges, characterised by
an increasing cross-linker/β-CD molar ratio, have been used as
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delivery systems for camptothecin. All proved to solubilise
camptothecin, thereby increasing its aqueous solubility, and
formed inclusion complexes. FTIR, DSC and XRPD analyses
confirmed the drug interaction with nanosponges. Moreover
camptothecin loaded in nanosponges was seen to be more effec-
tive than the plain drug on HT29 cells.
The same formulation was recently shown to be an effective
nanotechnology for the treatment of both androgen-sensitive
and castrate-refractory prostate cancer in cell-line experiments
[42].
Nanosponges can be used to store and prolong the release of
volatile molecules, such as essential oils, following their encap-
sulation. Linalool, a liquid component of many essential oils
and fragrances with a boiling point of 198 °C, was encapsu-
lated in different types of nanosponges as a liquid oil model
[43]. β-CD-1/4 nanosponges can incorporate 8% w/w of
linalool within their structure. The entrapment of linalool in the
nanosponge matrix was confirmed by DSC analysis. In vitro
release studies were carried out by using the linalool
β-cyclodextrin complex for comparative purposes. After 2
hours, linalool release from nanosponges was half that from the
β-cyclodextrin complex, thereby showing that nanosponges
stabilise the molecule in their structure.
Protein delivery
Swellable cyclodextrin-based nanosponges were purposely
prepared for protein delivery by using a different synthetic
route. New swellable cyclodextrin-based poly(amidoamine)
nanosponges (PAA-NS) [44], named NS 10 and NS 11, were
synthesised by cross-linking β-cyclodextrins with either 2,2-
bis(acrylamidoacetic acid) or a short polyamido-amine chain
der iv ing  f rom 2 ,2-b is (acry lamidoacet ic  ac id)  and
2-methylpiperazine, respectively. These swellable nanosponges
were shown to be sensitive to the pH of the surrounding media.
PAA-NS were reduced in nanosuspensions by using the high-
pressure-homoginisation technique. Bovine serum albumin
(BSA) was used as a model protein to study the encapsulating
capacity of these new β-cyclodextrin-based nanosponges. High
protein-complexation capacity was achieved for both the
nanosponges with a BSA-encapsulation efficiency greater than
90%. In vitro release studies were carried out, showing a
prolonged release of albumin from the two swellable β-CD-
nanosponges over a period of 24 h. The encapsulation of
albumin and its prolonged release was also obtained with
carbonate nanosponges (unpublished data).
NS10 and NS11 were recently used to incorporate lysozyme
and showed a high loading capacity. The encapsulation effi-
ciency and loading percentages were 89% and 17% for NS10
and 96% and 19.6 for NS11. These lysozyme-loaded
nanosponges released the enzyme at a pH-dependent rate with
prolonged kinetics, whilst maintaining its biological activity
[44].
Oral delivery systems
The dissolution rate of a solid drug is a limiting factor for oral
bioavailability. For hydrophobic drugs the dissolution process
acts as the rate-controlling step and, therefore, determines the
rate and degree of absorption. As a consequence, many
hydrophobic drugs show erratic and incomplete absorption from
the gastrointestinal tract.
The Biopharmaceutics Classification System (BCS) was devel-
oped by Amidon [45] in 1995 as a tool for predicting the extent
of drug absorption after oral administration. This system divides
drugs into four categories according to their solubility and
intestinal permeability. Formulation strategies can be used to
shift a drug from one class to another by improving their phar-
maceutical characteristics.
Acetylsalicylic acid (ASA), a nonsteroidal anti-inflammatory
drug belonging to BCS class III, was formulated into pyromel-
litic dianhydride cross-linked β-cyclodextrin nanosponges [36].
TEM studies showed that the particle sizes of ASA-loaded
nanosponges have average diameters ranging from 40 to 60 nm
and they were seen to have a regular spherical shape. Zeta
potential was high enough to obtain a stable colloidal formula-
tion. In vitro and in vivo studies indicated a slow and prolonged
ASA release from pyromellitic cross-linked β-cyclodextrin
nanosponges over a long period, i.e., 24 hours. In carrageenan-
induced rat paw edema, administration of ASA as a nanosponge
formulation administered by oral gavage reduced inflammation
significantly (P < 0.01 and P < 0.05) compared to plain ASA
and the control group. These results indicate that the ASA
nanosponge formulation may be used for oral delivery of the
drug.
Paclitaxel-loaded nanosponges were administered to rats by oral
gavage using commercially available TAXOL® as the control.
The oral bioavailability of the drug was increased about 3-fold
after the administration of paclitaxel-loaded nanosponges, in
comparison to the control [46].
More recently, Rao et al. studied the influence of carbonate
nanosponges on telmisartan, an antihypertensive BCS class II
drug characterised by an estimated solubility in water of just
9.9 μg/ml resulting in low bioavailability. The formation of a
ternary complex of telmisartan with nanosponges and NaHCO3
was seen to synergistically enhance the dissolution rate of
telmisartan [47].
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Topical delivery systems
Nanosponges can be used in gels or creams for topical applica-
tion. In one recent work, resveratrol, a polyphenolic phytoalexin
present in different plant sources and which plays an important
role in the prevention of many human diseases, particularly due
to its antioxidant properties, was encapsulated in nanosponges.
Incorporation markedly increased the solubility and stability of
the molecule.
Resveratrol-loaded nanosponges were seen to enhance drug
permeation in in vitro studies on porcine skin. Enhanced perme-
ation of resveratrol was also observed by using rabbit buccal
mucosa [48].
Gamma-oryzanol is a ferulic acid ester mixture, used as
sunscreen in the cosmetics industry. Its application is limited by
its high instability and photodegradation. Gamma-oryzanol was
encapsulated in nanosponges, showing a good protection from
photodegradation. A gel and an O/W emulsion were formulated
with the gamma-oryzanol-loaded nanosponges [49]. In vitro
permeability and accumulation studies were then carried out on
porcine skin. A high skin accumulation of gamma-oryzanol was
observed over time. The ability of nanosponges to increase the
uptake of the guest molecule by the skin can be attributed to the
capacity to increase solubility at the surface of the skin, as
already reported for cyclodextrins.
Gas delivery
Gas storage and delivery play an important role in biology,
medicine, cosmetics and pharmaceuticals. The molecular encap-
sulation of gases in cyclodextrin cavities has already been
proven. Nanosponge formulations can act as a reservoir for
various types of gas. β-CD nanosponges have shown an ability
to store large amounts of carbon dioxide, 1-methylcyclo-
propene and oxygen [8].
Three different cyclodextrin nanosponges were synthesised
cross-linking α-, β- or γ-cyclodextrin with carbonyldiimidazole
as oxygen-encapsulating formulations [50]. The nanosponges
were able to release oxygen both in the presence and in the
absence of ultrasound (US). Oxygen permeation through a sili-
cone membrane was obtained by using a nanosponge/hydrogel
combination system
All types of nanosponges were able to encapsulate, store and
release oxygen for prolonged periods. Ultrasound enhanced the
in vitro release and permeation of oxygen. The nanosponge/
hydrogel system produces a slower sustained release of the gas.
Therefore, nanosponges could be suitable carriers for topical
oxygen delivery in the presence and in the absence of US and
could act as an oxygen reservoir.
Conclusion
Nanosponges are a new type of biocompatible cross-linked
polymer, whose production is flexible and cost-effective.
Cyclodextrin nanosponges possess particular properties in terms
of their encapsulation ability, biocompatibility and solubilisa-
tion capacity with regard to different types of molecules.
Nanosponges could broaden the range of applications of
cyclodextrins in pharmacy and medicine, as well as in other
important fields, such as agriculture, cosmetics and the environ-
ment. They could be used to delivery two active substances
simultaneously for combination therapy, or for simultaneous
therapeutic and diagnostic applications. The surface engi-
neering of nanosponges could lead to prolonged residence time
in the blood or increased efficiency and specificity with ligands
for targeting sites. In conclusion, nanosponges can be consid-
ered as multifunctional nanoscale systems suitable for the
delivery of active molecules in nanomedicine.
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